Tag Archives: antibody patents

USPTO ARP Panel Restores MPF Sanity, but Still Rejects Xencor’s Claims

by Dennis Crouch

In a new Appeals Review Panel (ARP), the USPTO has clarified the Office’s position on means plus function claims — explaining that the specification need not describe statutory equivalents to satisfy the written description requirement.  The outcome here shows value for the intentional use of means-plus-function limitations as a mechanism for expanding patent scope when genus claims are otherwise unavailable.

Still the court maintained the written description rejection on other grounds — finding that the broad preamble “method of treating a patient” to be limiting and not adequately supported by the specification.  Perhaps on remand the patentee will amend the preamble to instead claim a “means of treating a patient.”  (more…)